Skip to main content
Medical information Clinical review pending

Genetic Testing

JAK 2 Exon 12 Mutation Detection Test

The JAK 2 Exon 12 Mutation Detection Test identifies specific genetic mutations in the JAK2 gene, often linked to certain blood cancers like myeloproliferative neoplasms. This test helps guide diagnosis and treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
3 mL (2 mL minimum) of whole blood collected in a Lavender Top (EDTA) tube.
Results
Confirm with the laboratory before booking.
Preparation
Please ensure a duly filled Genomics Clinical Information Requisition Form (Form 20) is provided with the sample. No specific patient preparation is required for this blood test.
Test priceKSh 15,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the JAK 2 Exon 12 Mutation Detection Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of myeloproliferative neoplasms
  • ✓Patients with symptoms suggestive of blood cancers
  • ✓Family history of blood cancers
  • ✓Monitoring disease progression
  • ✓Guiding treatment decisions
  • ✓Evaluating unexplained blood cell counts
02

In plain language

What this test helps you understand

This test helps identify specific mutations in the JAK2 gene associated with myeloproliferative neoplasms, aiding in diagnosis and guiding personalized treatment decisions.
The JAK 2 Exon 12 Mutation Detection Test is a diagnostic tool used in oncology to identify specific mutations within the JAK2 gene. These mutations are frequently associated with myeloproliferative neoplasms, a group of blood cancers. Understanding the presence of these mutations is crucial for accurate diagnosis and developing effective treatment strategies.

This test specifically looks for mutations in exon 12 of the JAK2 gene. These mutations can cause the body to produce too many blood cells, a characteristic feature of certain cancers. Identifying these mutations allows healthcare providers to better understand the underlying cause of the condition and tailor treatment plans to the individual patient's needs.

This test is particularly relevant for individuals diagnosed with myeloproliferative neoplasms or those presenting with symptoms suggestive of these conditions.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationPlease ensure a duly filled Genomics Clinical Information Requisition Form (Form 20) is provided with the sample. No specific patient preparation is required for this blood test.
Sample3 mL (2 mL minimum) of whole blood collected in a Lavender Top (EDTA) tube.
MethodologyConfirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects mutations specifically in exon 12 of the JAK2 gene. It does not detect mutations in other genes or other exons of the JAK2 gene. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test looks for specific changes (mutations) in the JAK2 gene, particularly in exon 12, which can be linked to certain types of blood cancer.
Identifying these mutations helps doctors diagnose conditions like myeloproliferative neoplasms more accurately and choose the most effective treatment plan.
Individuals diagnosed with myeloproliferative neoplasms, those with symptoms like fatigue or unexplained weight loss, or those with a family history of blood cancers may benefit from this test.
The test requires a blood sample collected in a specific type of tube (Lavender Top/EDTA).
Turnaround time varies. Please contact the laboratory for specific details.
No special preparation is needed for the blood draw itself. Ensure the required clinical information form is completed.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp